Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00209807
Status:
UNKNOWN
Last Update Posted:
2010-05-27
First Post:
2005-09-13
Brief Title:
Effect of Escitalopram vs Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
Sponsor:
Hospital Universitari Vall dHebron Research Institute
Organization:
Hospital Universitari Vall dHebron Research Institute
Study Overview
Official Title:
Effect of Escitalopram vs Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder a Randomized Double Blind Clinical Trial
Status:
UNKNOWN
Status Verified Date:
2010-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with major depressive disorder MDD commonly have many gastrointestinal complaints Gastrointestinal pain is classified into 2 categories visceral and somatic pain The main aim of this study is to compare somatic and visceral sensitivity between healthy people and pateints with MDD These two sensitivities will be assessed by the 2 following tests standardized rectal distension and Transdermal transcutaneous electric nerve stimulation Thereafter patients with MDD will be randomly allocated to escitalopram or reboxetine After 6 weeks of treatment somatic and visceral sensitivity will be reassessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None